|
MyBotsBlog -2M report
|
| Innovative Urine Test Offers Easy Screening for Autism in Children |
27/05/2026 |
«A groundbreaking scientific advancement has emerged from Arizona State University (ASU) that promises to revolutionize early autism spectrum disorder (ASD) detection...”an innovation that could dramatically transform the lives of millions.
Researchers have developed a novel urine-based diagnostic screening tool which detects unique biochemical signatures associated with autism in children as young as two years old.
This pioneering approach focuses on analyzing microbially-derived metabolites, small molecular compounds produced by the gut microbiota, which appear to be distinctly elevated in children with autism compared to typically developing peers.»...
|
|
|
bioengineer |
|
| Autisme et audition: des pistes pour eclairer un fonctionnement cerebral different - UdeMnouvelles |
20/05/2026 |
«Dans une étude récente menée en collaboration avec Luodi Yu, de l'Université de Guangzhou en Chine, le chercheur vient renforcer cette perspective: chez certains enfants autistes, le cerveau semble particulièrement apte à détecter de très fines variations sonores tout en éprouvant davantage de difficultés à traiter les séquences temporelles inhérentes au langage oral.»...
|
|
|
nouvelles.umontreal |
|
| Autism related traits and anxiety in the general population are linked through intolerance of uncertainty and affect labeling | Scientific Reports |
12/05/2026 |
«Abstract Anxiety is prevalent in autism spectrum disorder and linked to intolerance of uncertainty (IU). As a cognitive strategy, affect labeling (AL) reduces distress by structuring ambiguous sensations.
However, autistic individuals frequently exhibit AL deficits, raising a critical dilemma: a strategy alleviating uncertainty-driven anxiety is inherently difficult to access.
It is unclear whether IU paradoxically motivates AL use despite these deficits. In this cross-sectional study, 505 adults completed measures of autistic traits, IU, AL, and anxiety.
We tested two serial mediation models: the Cognitive-Motivational Model (CMM; IU motivates AL) and Emotion Regulation deficit Model (ERM; AL deficits increase IU). While both fit well, CMM was selected based on theoretical consistency.
This was consistent with established risk pathways where autistic traits relate to anxiety via higher IU and lower AL. Crucially, a novel adaptive pathway emerged: higher autistic traits were associated with higher IU, which were linked to higher AL and lower anxiety.
While these pathways represent theoretical assumptions rather than proven causality, the findings suggest a dual role of IU as risk factor and motivational driver. This may point to a conflict in individuals with high autistic traits: struggling with AL deficits yet motivated to use AL to cope with uncertainty.»...
|
|
|
nature |
|
| This app lets kids with disabilities use devices with their minds. Now anyone can download it | CBC Radio |
04/05/2026 |
«When Claire Sonnenberg was born with cerebral palsy, her parents were told she would never talk, walk or do much of anything on her own.Now the smart and smiley 10-year-old plays video games, bakes and makes smoothies and pores over books using a brain-computer interface (BCI), technology that allows her to control devices and communicate using only her thoughts."We hear her speak, we hear her say I love you, we hear her activate her jeep and drive across the lawn ...” it's magic," said Claire's mom, Stephanie Sonnenberg, who lives in Okotoks, Alta.»
[...]
«
How does it work?
Contrary to popular belief, BCI can’t read your mind, Kelly says. Instead, the app works like a translator, turning specific brainwaves into commands.
“You have to actually teach the system to recognize what your thoughts mean,” she said.
The headband needs to be calibrated each time it’s worn, which involves thinking of a specific word repeatedly, such as “go,” for several seconds. The Think2Switch system then understands that when detected, this brain signal means “go.” The process is repeated for other basic commands.
»...
|
|
|
cbc |
|
| Autisme : la Haute Autorite de Sante recommande des interventions precoces, avant meme le diagnostic |
28/04/2026 |
«Autisme : la Haute Autorité de Santé recommande des interventions précoces, avant même le diagnosticDès le repérage des premiers signes évoquant un possible trouble du spectre autistique, des interventions comportementales et développementales précoces sont préconisées, y compris chez le nourrisson.
Décryptage avec le Dr Martine Collot, pédopsychiatre, chef du pôle psychiatrique infanto-juvénile à l'hôpital de Toulon La Seyne).»...
|
|
|
nicematin |
|
| FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | FDA |
24/04/2026 |
«The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene.Following the publication of powerful results of hearing restoration in the New England Journal of Medicine, the FDA acted swiftly to grant a national priority voucher for an accelerated review.»...
|
|
|
fda |
|
| FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | FDA |
24/04/2026 |
«The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene.Following the publication of powerful results of hearing restoration in the New England Journal of Medicine, the FDA acted swiftly to grant a national priority voucher for an accelerated review.»...
|
|
|
fda |
|
| FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | FDA |
24/04/2026 |
«The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene.Following the publication of powerful results of hearing restoration in the New England Journal of Medicine, the FDA acted swiftly to grant a national priority voucher for an accelerated review.»...
|
|
|
fda |
|
| Examining the link between newborn hearing tests and autism risk | MSUToday | Michigan State University |
07/04/2026 |
«Hearing tests administered to most newborn babies in Michigan could hold clues to which ones might later be diagnosed with neurodevelopmental conditions, such as autism spectrum disorder.Such a finding could identify at-risk children who could benefit from early interventions, and support their participation in family, school, and community activities, said Nicole Talge, a College of Human Medicine developmental psychologist and associate professor of epidemiology and biostatistics.»...
|
|
|
msutoday.msu |
|
| MARSEILLE : Autisme - L'IA renverse le match et arrache une victoire inesperee pour le traitement - Presse Agence |
29/03/2026 |
«L'IA révèle l'efficacité d'un traitement pour l'autisme, transformant un échec clinique cuisant en une victoire pleine d'espoir.Le coup de sifflet final avait sonné comme une défaite sans appel.
Sur le terrain impitoyable de la recherche médicale, le bumétanide, ce champion que l'on croyait invincible après une série de victoires éclatantes en phase 2, venait de s'incliner.
Deux essais cliniques de phase 3, l'équivalent d'une finale de coupe du monde, s'étaient soldés par un échec cuisant. Pour les familles et les chercheurs engagés dans le combat contre les troubles du spectre de l'autisme (TSA), qui touchent près de 2 % des enfants, la douche fut glaciale.
Dans ce domaine orphelin de tout traitement médicamenteux validé pour ses symptômes centraux, l'espoir semblait s'évanouir.»
[...]
« La machine a parlé : le bumétanide ne perdait pas le match, il le gagnait, mais sur une partie bien précise du terrain. L’étude révèle que pour 30 à 40 % des enfants, le traitement s’est avéré significativement plus efficace que le placebo. Une victoire nette, passée totalement inaperçue dans le vacarme du résultat global.
L’IA a même dressé le portrait-robot de ces « répondants ». Il s’agit d’enfants présentant des caractéristiques cliniques spécifiques : une difficulté modérée à s’adapter au changement, des comportements répétitifs marqués par un besoin de routines, et des difficultés sociales prononcées. Des critères déjà connus des médecins, ne nécessitant aucun test complexe. La clé n’était pas dans de nouvelles données, mais dans une lecture plus fine, plus tactique, du jeu. « Nos résultats confirment une idée simple : le même traitement ne peut pas fonctionner chez tous les enfants autistes. Il faut identifier, dès le départ, les profils cliniques qui peuvent en bénéficier », martèle le Pr Ben-Ari.
»...
|
|
|
presseagence |
|
|
|